Pesquisas alternativas:
doses developing » does developing (Expandir a Pesquisa), cases developing (Expandir a Pesquisa), masses developing (Expandir a Pesquisa)
costs developing » cysts developing (Expandir a Pesquisa), courts developing (Expandir a Pesquisa), cases developing (Expandir a Pesquisa)
care developing » late developing (Expandir a Pesquisa), care development (Expandir a Pesquisa)
developing type » developing novel (Expandir a Pesquisa)
drug care » drugs care (Expandir a Pesquisa), drug card (Expandir a Pesquisa), drug case (Expandir a Pesquisa)
doses developing » does developing (Expandir a Pesquisa), cases developing (Expandir a Pesquisa), masses developing (Expandir a Pesquisa)
costs developing » cysts developing (Expandir a Pesquisa), courts developing (Expandir a Pesquisa), cases developing (Expandir a Pesquisa)
care developing » late developing (Expandir a Pesquisa), care development (Expandir a Pesquisa)
developing type » developing novel (Expandir a Pesquisa)
drug care » drugs care (Expandir a Pesquisa), drug card (Expandir a Pesquisa), drug case (Expandir a Pesquisa)
1
2
“... risks we considered the relevance to AD drug development of the following factors: (1) effective dosing...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
Por Sattar, Naveed
Publicado em 2014
“...As is well known, diabetes rates continue to escalate worldwide, adding cost and disease burden...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Yildirim, Oktay, Gottwald, Matthias, Schüler, Peter, Michel, Martin C.
Publicado no Front Pharmacol (2016)
“...Drug development faces the double challenge of increasing costs and increasing pressure on pricing...”Publicado no Front Pharmacol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
“... secondary non-adherence rate of 50%, for all types of drugs, the acquisition cost related to non-adherence...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
Por Elisa S. Roesti, Christina N. Boyle, Daniel T. Zeman, Marcos Sande-Melon, Federico Storni, Gustavo Cabral-Miranda, Alexander Knuth, Thomas A. Lutz, Monique Vogel, Martin F. Bachmann
Publicado em 2020-03-01
“...Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by insulin...”Publicado em 2020-03-01
Obter o texto integral
Artigo
7
Por Gæde, Peter, Valentine, William J., Palmer, Andrew J., Tucker, Daniel M.D., Lammert, Morten, Parving, Hans-Henrik, Pedersen, Oluf
Publicado em 2008
Assuntos:
“...Clinical Care/Education/Nutrition/Psychosocial Research...”Publicado em 2008
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Jha, Ashish K., Kuperman, Gilad J., Teich, Jonathan M., Leape, Lucian, Shea, Brian, Rittenberg, Eve, Burdick, Elisabeth, Seger, Diane Lew, Vliet, Martha Vander, Bates, David W.
Publicado em 1998
“...Abstract Background: Adverse drug events (ADEs) are both common and costly. Most hospitals identify...”Publicado em 1998
Obter o texto integral
Obter o texto integral
Artigo
9
Por Hass, Bastian, Pooley, Jayne, Feuring, Martin, Suvarna, Viraj, Harrington, Adrian E.
Publicado em 2012
Assuntos:
“...Health Care...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Por Bruce Guthrie, Alexander Thompson, Siobhan Dumbreck, Angela Flynn, Phil Alderson, Moray Nairn, Shaun Treweek, Katherine Payne
Publicado em 2017-04-01
Assuntos:
“...quality of health-care...”Publicado em 2017-04-01
Obter o texto integral
Artigo
11
“... from the provision of long term institutional care in most developed countries, there is a growing...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
“...Because of the high cost of investigational drugs, the strict legal requirements for recordkeeping...”
Obter o texto integral
Obter o texto integral
Artigo
13
“... dependent on the drug’s pharmacological action and dose. Common Type B reactions seen in clinical practice...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
“... done, and generic drug prescribed for 3 months — Rosart (Actavis) in analogous doses. Patients were...”
Obter o texto integral
Obter o texto integral
Artigo
15
Por Coenen, Martin, Hinze, Annette Viktoria, Mengel, Martin, Fuhrmann, Christine, Lüdenbach, Bastian, Zimmermann, Julian, Dykstra, Verena, Fimmers, Rolf, Viviani, Roberto, Stingl, Julia, Holdenrieder, Stefan, Müller, Marcus, Hartmann, Gunther, Coch, Christoph
Publicado no BMC Pharmacol Toxicol (2015)
“... the dose steps within the first-in-human trial with a newly developed RIG-I ligand. Thus, ResI is a...”Publicado no BMC Pharmacol Toxicol (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Goswami, Avranil, Chakraborty, Urmita, Mahapatra, Tanmay, Mahapatra, Sanchita, Mukherjee, Tapajyoti, Das, Shibali, Das, Aritra, Dey, Subir Kumar, Ray, Sudhin, Bhattacharya, Basudev, Pal, Nishith Kumar
Publicado em 2014
“... the prevailing scenario owing to increased duration, cost and toxicity associated with the treatment of drug...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
“... of lactose in drugs is often limited.
This data could positively impact the quality of care for lactose...”
Obter o texto integral
Obter o texto integral
Artigo
18
“... and discuss costs, outcomes and some of the challenges of diabetes care in Italy in the context of recent...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
Por Field, Terry S, Rochon, Paula, Lee, Monica, Gavendo, Linda, Baril, Joann L, Gurwitz, Jerry H
Publicado em 2010
“... estimated the cost of developing the CDSS as $48,668.57. Drug costs saved during the 12 months of the trial...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Artigo
20
“... characterized as mild, moderate, or severe and as type A (dose-dependent or predictable) or type B...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo